Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Capital Expenditures (2016 - 2022)

Aptevo Therapeutics' Capital Expenditures history spans 7 years, with the latest figure at $4000.0 for Q3 2022.

  • For Q3 2022, Capital Expenditures fell 69.23% year-over-year to $4000.0; the TTM value through Dec 2022 reached $135000.0, down 81.07%, while the annual FY2022 figure was $29000.0, 95.93% down from the prior year.
  • Capital Expenditures for Q3 2022 was $4000.0 at Aptevo Therapeutics, down from $118000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $927000.0 in Q3 2018 and bottomed at $4000.0 in Q3 2022.
  • The 4-year median for Capital Expenditures is $191000.0 (2021), against an average of $315222.2.
  • The largest annual shift saw Capital Expenditures soared 586.67% in 2018 before it tumbled 69.23% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at $927000.0 in 2018, then crashed by 83.5% to $153000.0 in 2019, then fell by 22.88% to $118000.0 in 2021, then plummeted by 96.61% to $4000.0 in 2022.
  • Per Business Quant, the three most recent readings for APVO's Capital Expenditures are $4000.0 (Q3 2022), $118000.0 (Q4 2021), and $13000.0 (Q3 2021).